Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Insulet Corp (NQ: PODD )

265.46 -2.12 (-0.79%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 443,137
Open 267.39
Bid (Size) 258.88 (1)
Ask (Size) 273.03 (1)
Prev. Close 267.58
Today's Range 264.69 - 270.29
52wk Range 160.19 - 279.40
Shares Outstanding 68,873,869
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Insulet Successfully Defends its Intellectual Property Against EOFlow Co. in U.S. District Court
From Insulet Corporation
Via Business Wire
Novocure Stock Earns 96 RS Rating
On Tuesday, Novocure stock got a positive adjustment to its Relative Strength (RS) Rating to 96, up from 73. 
Via Investor's Business Daily

Performance

YTD
+26.95%
+26.95%
1 Month
+10.93%
+10.93%
3 Month
+23.62%
+23.62%
6 Month
+38.68%
+38.68%
1 Year
+36.46%
+36.46%

More News

Read More
Peering Into Insulet's Recent Short Interest
Via Benzinga
NASDAQ:PODD qualifies as a high growth stock and is consolidating.
Via Chartmill
Insulet Announces Omnipod® 5 System is Now Compatible with Abbott’s FreeStyle Libre 2 Plus Sensor in the U.S.
From Insulet Corporation
Via Business Wire
9 Analysts Have This To Say About Insulet
Via Benzinga
Why NASDAQ:PODD qualifies as a high growth stock.
Via Chartmill
Insulet to Present at Upcoming Investor Conferences
From Insulet Corporation
Via Business Wire
Top 4 Health Care Stocks That May Plunge This Quarter
Via Benzinga
S&P 500 Breaks 6,000 Points, Dow Soars Above 44,000, Small Caps Eye Strongest Week In 4 Years, Tesla Hits $1 Trillion: What's Driving Markets Friday?
Via Benzinga
Topics Stocks
Exposures US Equities
(PODD) - Analyzing Insulet's Short Interest
Via Benzinga
Here's How Much $1000 Invested In Insulet 10 Years Ago Would Be Worth Today
Via Benzinga
Is NASDAQ:PODD on the Verge of a Major Breakout as a Strong Growth Stock?
Via Chartmill
Insulet Soars Out Of Buy Zone As 'Beat-And-Raise Cadence' Continues
Via Investor's Business Daily
High growth, ROE and relative strength for NASDAQ:PODD, growth investors may appreciate this.
Via Chartmill
Insulet Reports Third Quarter 2024 Revenue Increase of 26% Year-Over-Year (25% Constant Currency1)
From Insulet Corporation
Via Business Wire
This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Insulet Announces Array of Activities to Support National Diabetes Awareness Month and World Diabetes Day in November
From Insulet Corporation 
Via Business Wire
If You Invested $100 In This Stock 10 Years Ago, You Would Have $600 Today
Via Benzinga
Omnipod® 5 App for iPhone® Now Fully Available in the United States
From Insulet Corporation
Via Business Wire
Solventum Stock Earns 81 RS Rating
Via Investor's Business Daily
Analyst Ratings For Insulet
Via Benzinga
Is NASDAQ:PODD a Fit for high Growth Investing Strategies?
Via Chartmill
Exploring the Growth Potential of NASDAQ:PODD as It Nears a Breakout.
Via Chartmill
Insulet to Announce Third Quarter 2024 Financial Results on November 7, 2024
From Insulet Corporation
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.